Therapeutic potential of monoamine transporter substrates

Current Topics in Medicinal Chemistry

Volumn 6, Issue 17, 2006, Pages 1845-1859

  Rothman, Richard B ^a   Baumann, Michael H ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Amphetamine; Dopamine; PAL 287; Release; Serotonin; Transporters

Indexed keywords

ALPHA METHYLNAPTHYLETHYLAMINE; AMFEPRAMONE; AMINE OXIDASE (FLAVIN CONTAINING); AMINOREX; AMPHETAMINE; CARRIER PROTEIN; CHLORPHENTERMINE; CITALOPRAM; COCAINE; DESIPRAMINE; DOPAMINE TRANSPORTER; EPHEDRINE; FENFLURAMINE; FLUOXETINE; MAZINDOL; METHAMPHETAMINE; METHYLPHENIDATE; MONOAMINE TRANSPORTER; NORADRENALIN; PAL 287; PEMOLINE; PHENDIMETRAZINE; PHENMETRAZINE; PHENTERMINE; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT; SEROTONIN; SEROTONIN TRANSPORTER; TYRAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ANOREXIA; ATTENTION DEFICIT DISORDER; CARDIOVASCULAR DISEASE; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; FEASIBILITY STUDY; GENE TARGETING; HUMAN; IN VITRO STUDY; MENTAL DISEASE; NONHUMAN; PULMONARY HYPERTENSION; REVIEW; RHESUS MONKEY; STRUCTURE ANALYSIS;

ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; MOLECULAR CONFORMATION; SUBSTANCE-RELATED DISORDERS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 33748658464     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802606778249766     Document Type: Review

References (94)

1. Wise, R.A. Neurobiology of addiction. Curr. Opin. Neurobiol. 1996, 6, 243-251.
2. Wee, S.; Carroll, F.I.; Woolverton, W.L. A Reduced Rate of In Vivo Dopamine Transporter Binding is Associated with Lower Relative Reinforcing Efficacy of Stimulants. Neuropsychopharmacology 2006, 31 (2), 351-62.
3. Woolverton, W.L.; Wang, Z. Relationship between injection duration, transporter occupancy and reinforcing strength of cocaine. Eur J Pharmacol. 2004, 486 (3), 251-7.
4. Amara, S.G.; Kuhar, M.J. Neurotransmitter transporters: recent progress. Ann. Rev. Neurosci. 1993, 16, 73-93.
5. Masson, J.; Sagne, C.; Hamon, M.; el Mestikawy, S. Neurotransmitter transporters in the central nervous system. Pharmacol. Rev. 1999, 51, 439-464.
6. Blakely, R.D.; De Felice, L.J.; Hartzell, H.C. Molecular physiology of norepinephrine and serotonin transporters. [Review]. J. Exp. Biol. 1994, 196, 263-281.
7. Uhl, G.R.; Johnson, P.S. Neurotransmitter transporters: three important gene families for neuronal function. J. Exp. Biol. 1994, 196, 229-236.
8. Amara, S.G.; Souders, M.S. Neurotransmitter transporters as molecular targets for addictive drugs. Drug Alcohol. Depend. 1998, 51, 87-96.
9. Ulus, I.H.; Maher, T.J.; Wurtman, R.J. Characterization of phentermine and related compounds as monoamine oxidase (mao) inhibitors. Biochem. Pharmacol. 2000, 59, 1611-1621.
10. 3H]dopamine from rat striatal synaptic vesicles: comparison with d-amphetamine. J. Neurochem. 1998, 71 (1), 258-65.
11. Rudnick, G.; Clark, J. From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters. [Review]. Biochimica et Biophysica Acta 1993, 1144, 249-263.
12. pp 73-100.
13. Blakely, R.D.; Defelice, L.J.; Galli, A. Biogenic amine neurotransmitter transporters: just when you thought you knew them. Physiology (Bethesda). 2005, 20, 225-31.
14. Sine, H.H.; Freissmuth, M. Oligomer formation by Na+-Cl - coupled neurotransmitter transporters. Eur. J. Pharmacol. 2003, 479 (1-3), 229-36.
15. Sulzer, D.; Souders, M.S.; Poulsen, N.W.; Galli, A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog. Neurobiol. 2005, 75 (6), 406-33.
16. Nightingale, B.; Dersch, C.M.; Boos, T.L.; Greiner, E.; Calhoun, W.J.; Jacobson, A.E.; Rice, K.C.; Rothman, R.B. Studies of the Biogenic Amine Transporters. XI. Identification of a 1-[2-[Bis(4- fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR-12909) Analog That Allosterically Modulates the Serotonin Transporter. J. Pharmacol. Exp. Ther. 2005, 314 (2), 906-15.
17. Chen, F.; Larsen, M.B.; Neubauer, H.A.; Sanchez, C.; Plenge, P.; Wiborg, O. Characterization of an allosteric citalopram-binding site at the serotonin transporter. J. Neurochem. 2005, 92 (1), 21-8.
18. Nandi, A.; Dersch, C.M.; Kulshrestha, M.; Ananthan, S.; Rothman, R.B. Identification and characterization of a novel allosteric modulator (SoRI-6238) of the serotonin transporter. Synapse 2004, 53 (3), 176-83.
19. Rothman, R.B.; Dersch, C.M.; Carroll, F.I.; Ananthan, S. Studies of the biogenic amine transporters. VIII: identification of a novel partial inhibitor of dopamine uptake and dopamine transporter binding. Synapse 2002, 43 (4), 268-74.
20. 3H]Cocaine labels a binding site associated with the serotonin transporter in guinea pig brain: allosteric modulation- by paroxetine. Neurochem. Res. 1992, 17, 1275-1283.
21. Rothman, R.B.; Blough, B.E.; Woolverton, W.L.; Anderson, K.G.; Negus, S.S.; Mello, N.K.; Roth, B.L.; Baumann, M.H. Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration. J. Pharmacol. Exp. Ther. 2005, 313 (3), 1361-9.
22. Rothman, R.B.; Baumann, M. Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol. Ther. 2002, 95 (1), 73-88.
23. Rothman, R.B.; Baumann, M.H. Serotonin releasing agents. Neurochemical, therapeutic and adverse effects. Pharmacol. Biochem. Behav. 2002, 71 (4), 825-36.
24. Prisinzano, T.; Rice, K.C.; Baumann, M.H.; Rothman, R.B. Development of neurochemical normalization ("agonist substitution") therapeutics for stimulant abuse: focus on the dopamine uptake inhibitor, GBR12909. Curr. Med. Chem. (CNSA). 2004, 4(1), 47-59.
25. Rothman, R.B.; Baumann, M.H. Monoamine transporters and psychostimulant drugs. Eur. J. Pharmacol. 2003, 479 (1-3), 23-40.
26. Pineyro, G.; Blier, P. Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol. Rev. 1999, 51, 533-591.
27. Adell, A.; Artigas, F. Differential effects of clomipramine given locally or systemically on extracellular 5-hydroxytryptamine in raphe nuclei and frontal cortex. An in vivo brain microdialysis study. Naunyn Schmiedebergs. Arch. Pharmacol. 1991, 343, 237-244.
28. Rutter, J.J.; Gundlah, C.; Auerbach, S.B. Systemic uptake inhibition decreases serotonin release via somatodendritic autoreceptor activation. Synapse 1995, 20, 225-233.
29. Smith, J.E.; Lakoski, J.M. Electropbysiological effects of fluoxetine and duloxetine in the dorsal raphe nucleus and hippocampus. Eur. J. Pharmacol. 1997, 323, 69-73.
30. Hinerth, M.A.; Collins, H.A.; Baniecki, M.; Hanson, R.N.; Waszczak, B.L. Novel in vivo electrophysiological assay for the effects of cocaine and putative "cocaine antagonists" on dopamine transporter activity of substantia nigra and ventral tegmental area dopamine neurons. Synapse 2000, 38, 305-312.
31. 2-adrenoceptors in the locus coeruleus are involved in the in vivo modulation of cortical noradrenaline release by the antidepressant desipramine. J. Neurochem. 1998, 71, 790-798.
32. Florin, S.M.; Kuczenski; R.; Segal, D.S. Regional extracellular norepinephrine responses to amphetamine and cocaine and effects of clondine pretreatment. Brain Res. 1994, 654, 53-62.
33. Gundlah, C.; Martin, K.F.; Heal, D.J.; Auerbach, S.B. In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor. J. Pharmacol. Exp. Ther. 1997, 283, 581-591.
34. Gardier, A.M.; Trillat, A.C.; Malagic, I.; Jacquot, C. 8-OH-DPAT attenuates the dexfenfluramine-induced increase in extracellular serotonin: an in vivo dialysis study. Eur. J. Pharmacol. 1994, 265, 107-110.
35. Kamal, L.A.; Arbilla, S.; Langer, S.Z. Presynaptic modulation of the release of dopamine from the rabbit caudate nucleus: differences between electrical stimulation, amphetamine and tyramine. J. Pharmacol. Exp. Ther. 1981, 216 (3), 592-8.
36. Kuczenski, R.; Segal, D.S.; Manley, L.D. Apomorphine does not alter amphetamine-induced dopamine release measured in striatal dialysates. J. Neurochem. 1990, 54 (5), 1492-9.
37. Scorza, C.; Silveira, R.; Nichols, D.E.; Reyes-Parada, M. Effects of 5-HT-releasing agents on the extracellullar hippocampal 5-HT of rats. Implications for the development of novel antidepressants with a short onset of action. Neuropharmacology 1999, 38 (7), 1055-61.
38. Berger, U.V.; Gu, X.F.; Azmitia, E.C. The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. Eur. J. Pharmacol. 1992, 215, 153-160.
39. Crespi, D. Carrier-dependent and Ca(2+)-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methyl-endioxymethamphetamine, p-chloroamhetamine and (+)-fenfluramine. Br. J. Pharmacol. 1997, 121, 1735-143.
40. Rothman, R.B.; Baumann, M.H.; Dersch, C.M.; Romero, D.V.; Rice, K.C.; Carroll, F.I.; Partilla, J.S. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 2001, 39, 32-41.
41. Rothman, R.B.; Katsnelson, M.; Vu, N.; Partilla, J.S.; Dersch, C.M.; Blough, B.E.; Baumann, M.H. Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur. J. Pharmacol. 2002, 447 (1), 51-7.
42. Rothman, R.B.; Clark, R.D.; Partilla, J.S.; Baumann, M.H. (+)-fenfluramine and its major metabolite (+)-norfenfluramine, are potent substrates for norepinephrine transporters. J. Pharmacol. Exp. Ther. 2003, 305 (3), 1191-9.
43. Rothman, R.B.; Vu, N.; Partilla, J.S.; Roth, B.L.; Hufeisen, S.J.; Compton-Toth, B.A.; Birkes, J.; Young, R.; Glennon, R.A. In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates. J. Pharmacol. Exp. Ther. 2003, 307(1), 138-145.
44. Rothman, R.B.; Partilla, J.S.; Baumann, M.H.; Dersch, C.M.; Carroll, F.I.; Rice, K.C. Neurochemical neutralization of methamphetamine with high affinity non-selective inhibitors of biogenic amine transporters: a pharmacological strategy for treating stimulant abuse. Synapse 2000, 35, 222-227.
45. Griffiths, R.R.; Winger, G.; Brady, J.V.; Snell, J.D. Comparison of behavior maintained by infusions of eight phenylethylamines in baboons. Psychopharmacology 1976, 50, 251-258.
46. Corwin, R.L.; Woolverton, W.L.; Schuster, C.R.; Johanson, C.E. Anorectics: effects on food intake and self-administration in rhesus monkeys. Alcohol. Drug Res. 1987, 7, 351-361.
47. Evans, S.M.; Johanson, C.E. Amphetamine-like effects of anorectics and related compounds in pigeons. J. Pharmacol. Exp. Ther. 1987, 241, 817-825.
48. Wood, D.M.; Emmett Oglesby, M.W. Substitution and cross-tolerance profiles of anorectic drugs in rats trained to detect the discriminative stimulus properties of cocaine. Psychopharmacology 1988, 95, 364-368.
49. Wojnicki, F.H.E.; Rothman, R.B.; Rice, K.C.; Glowa, J.R. Effects of phentermine on responding maintained under multiple fixed-ratio schedules of food-presentation and cocaine-delivery in the rhesus monkey. J. Pharmacol. Exp. Ther. 1999, 288, 550-560.
50. Glowa, J.R.; Rice, K.C.; Matecka, D.; Rothman, R.B. Phentermine/ fenfluramine decreases cocaine self-administration in rhesus monkeys. Neuroreport 1997, 8, 1347-1351.
51. Munzar, P.; Baumann, M.H.; Shoaib, M.; Goldberg, S.R. Effects of dopamine and serotonin-releasing agents on methamphetamine discrimination and self-administration in rats. Psychopharmacology (Berl). 1999, 141, 287-296.
52. Stafford, D.; LeSage, M.G.; Rice, K.C.; Glows, J.R. A comparison of cocaine, GBR 12909, and phentermine self-administration by rhesus monkeys on a progressive-ratio schedule. Drug Alcohol. Dopend. 2001, 62, 41-47.
53. Glatz, A.C.; Ehrlich, M.; Bae, R.S.; Clarke, M.J.; Quinlan, P.A.; Brown, E.C.; Rada, P.; Hoebel, B.G. Inhibition of cocaine self-administration by fluoxetine or D-fenfluramine combined with phentermine. Pharmacol. Biochem. Behav. 2002, 71 (1-2), 197-204.
54. Rothman, R.B.; Blough, B.E.; Baumann, M.H. Appetite suppressants as agonist substitution therapies for stimulant dependence. Ann. N. Y. Acad. Sci. 2002, 965, 109-26.
55. Baumann, M.H.; Ayestas, M.A.; Dersch, C.M.; Brockington, A.; Rice, K.C.; Rothman, R.B. Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: therapeutic implications. Synapse 2000, 36, 102-113.
56. Alexander, M.; Rothman, R.B.; Baumann, M.H.; Endres, C.J.; Brasic, J.R.; Wong, D.F. Noradrenergic and dopaminergic effects of (+)-amphetamine-like stimulants in the baboon Papio anubis, Synapse 2005, 56 (2), 94-9.
57. Stead, A.H.; Moffat, A.C. A collection of therapeutic, toxic and fatal blood drug concentrations in man. Hum. Toxicol. 1983, 2 (3), 437-64.
58. Baselt, R.C., Disposition of toxic drugs and chemicals in man, 6th edition. ed.; Biomedical Publications: Foster City, CA, 2002; 'Vol.' p.
59. Brauer, L.H.; Johanson, C.E.; Schuster, C.R.; Rothman, R.B.; de Wit, H. Evaluation of phentermine and fenfluramine, alone and in combination, in normal, healthy volunteers. Neuropsychopharmacology 1996, 14, 233-241.
60. Martin, W.R.; Sloan, J.W.; Sapira, J.D.; Jasinski, D.R. Physiologic, subjective, and behavioral effects of amphetamine, mediamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin. Pharmacol. Ther. 1971, 12, 245-258.
61. Angrist, B.; Rotrosen, J.; Kleinberg, D.; Merriam, V.; Gershon, S. Dopaminergic agonist properties of ephedrine - theoretical implications. Psychopharmacology (Berl). 1977, 55, 115-120.
62. Gotestam, K.G.; Andersson, B.E. Assessment of reinforcing properties of amphetamine analogues in self-administering rats. Postgrad. Med. J. 1975, 51 (Suppl 1), 80-83.
63. Yu, H.; Kim, I.J.; Folk, J.E.; Tian, X.; Rothman, R.B.; Baumann, M.H.; Dersch, C.M.; Flippen-Anderson, J.L.; Parrish, D.; Jacobson, A.E.; Rice, K.C. Synthesis and pharmacological evaluation of 3- (3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters. J. Med. Chem. 2004, 47 (10), 2624-34.
64. Cunningham, J.K.; Liu, L.M. Impacts of federal precursor chemical regulations on methamphetamine arrests. Addiction 2005, 100 (4), 479-88.
65. Haller, C.A.; Benowitz, N.L. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N. Engl. J. Med. 2000, 343 (25), 1833-8.
66. Gilman, A.G.; Goodman, L.S.; Gilman, A.; Goodman and Gilman's the pharmacological basis of therapeutics. ed.; Pergammon Press: New York, 1992; 'Vol.'p.
67. Connolly, H.M.; McGoon, M.D. Obesity drugs and the heart. Curr. Probl. Cardiol. 1999, 24, 745-792.
68. Rothman, R.B.; Ayestas, M.A.; Dersch, C.M.; Baumann, M.H. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates: implications for primary pulmonary hypertension. Circulation 1999, 100, 869-875.
69. Launay, J.M.; Herve, P.; Peoch, K; Tournois, C.; Callebert, J.; Nebigil, C.G.; Etienne, N.; Drouet, L.; Humbert, M.; Simonneau, G.; Maroteaux, L. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat. Med. 2002, 8 (10), 1129-35.
70. Gurtner, H.P. Aminorex and pulmonary hypertension. Cor. Vasa. 1985, 27, 160-171.
71. Gaine, S.P.; Rubin, L.J.; Kmetzo, J.J.; Palevsky, H.I.; Traill, T.A. Recreational use of aminorex and pulmonary hypertension. Chest 2000, 118 (5), 1496-7.
72. 2B receptors in the cardiopathy associated with fenfluramine. Mol. Pharmacol. 2000, 57, 75-81.
73. 2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000, 102, 2836-2841.
74. Setola, V.; Hufeisen, S.J.; Grande-Allen, K.J.; Vesely, I.; Glennon, R.A.; Blough, B.; Rothman, R.B.; Roth, B.L. 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") Induces Fenfluramine-Like Proliferative Actions on Human Cardiac Valvular Interstitial Cells in Vitro. Mol. Pharmacol. 2003, 63 (6), 1223-9.
75. Baumann, M.H.; Wang, X.; Rothman, R.B. 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology (Berl) 2006.
76. Baumann, M.H.; Ayestas, M.A.; Detach, C.M.; Rothman, R.B. 1- (m-Chlorophenyl)piperazine (mCPP) Dissociates In Vivo Serotonin Release from Long-Term Serotonin Depletion in Rat Brain. Neuropsychopharmacology 2001, 24, 492-501.
77. Nichols, D.E.; Brewster, W.K.; Johnson, M.P.; Oberlender, R.; Riggs, R.M. Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA). J. Med. Chem. 1990, 33, 703-710.
78. Grabowski J.; Rhoades, H.; Stotts, A.; Cowan, K.; Kopecky, C.; Dougherty, A.; Moeller, F.G.; Hassan, S.; Schmitz, J. Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. Neuropsychopharmacology 2004, 29 (5), 969-81.
79. Negus, S.S.; Mello, N.K. Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a second-order schedule in rhesus monkeys. Drug Alcohol. Depend. 2003, 70 (1), 39-52.
80. Negus, S.S.; Mello, N.K. Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a progressive-ratio schedule in rhesus monkeys. Psychopharmacology (Berl). 2003, 167 (3), 324-32.
81. Grabowski, J.; Rhoades, H.; Schmitz, J.; Stotts, A.; Daruzska, L.A.; Creson, D.; Moeller, F.G. Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J. Clin. Psychopharmacol. 2001, 21 (5), 522-6.
82. Shearer, J.; Wodak, A.; van Beek, I.; Mattick, R.P.; Lewis, J. Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence. Addiction 2003, 98 (8), 1137-41.
83. pp 103-122.
84. Baumann, M.H.; Rothman, R.B. Alterations in serotonergic responsiveness during cocaine withdrawal in rats: similarities to major depression in humans. Biol. Psychiatry 1998, 44(7), 578-91.
85. Rothman, R.B.; Baumann, M.H. Neurochemical mechanisms of phentermine and fenfluramine: therapeutic and adverse effects. Drug Dev. Res. 2000, 51, 52-65.
86. Wee, S.; Anderson, K.G.; Baumann, M.H.; Rothman, R.B.; Blough, B.E.; Woolverton, W.L. Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs. J. Pharmacol. Exp. Ther. 2005, 313 (2), 848-54.
87. Fantegrossi, W.E.; Kiessel, C.L.; Leach, P.T.; Van Martin, C.; Karabenick, R.L.; Chen, X.; Ohizumi, Y.; Ullrich, T.; Rice, K.C.; Woods, J.H. Nantenine: an antagonist of the behavioral and physiological effects of MDMA in mice. Psychopharmacology (Berl). 2004, 173 (3-4), 270-7.
88. Kitson, R.; Carr, B. Tramadol and severe serotonin syndrome. Anaesthesia 2005, 60 (9), 934-5.
89. Barann, M.; Urban, B.; Stamer, U.; Dorner, Z.; Bonisch, H.; Bruss, M. Effects of tramadol and O-demethyl-tramadol on human 5-HT reuptake carriers and human 5-HT3A receptors: a possible mechanism for tramadol-induced early emesis. Eur. J. Pharmacol. 2006, 531 (1-3), 54-8.
90. Thomas, J.B.; Atkinson, R.N.; Rothman, R.B.; Fix, S.E.; Mascarella, S.W.; Vinson, N.A.; Xu, H.; Dersch, C.M.; Lu, Y.; Cantrell, B.E.; Zimmerman, D.M.; Carroll, F.I. Identification of the first trans-(3R,4R)- dimethyl4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid kappa receptor antagonist activity. J. Med. Chem. 2001, 44 (17), 2687-90.
91. Beardsley, P.M.; Howard, J.L.; Shelton, K.L.; Carroll, F.I. Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. Psychopharmacology (Berl). 2005, 1-9.
92. 3H]DA-uptake-inhibition to transporter-binding-inhibition ratios for the in vitro evaluation of putative cocaine antagonists. Life Sci. 1993, 53, PL267-PL272.
93. Baumann, M.H.; Clark, R.D.; Budzynski, A.G.; Partilla, J.S.; Blough, B.E.; Rothman, R.B. N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy). Neuropsychopharmacology 2005, 30 (3), 550-60.
94. Yu, H.; Rothman, R.B.; Dersch, C.M.; Partilla, J.S.; Rice, K.C. Uptake and release effects of diethylpropion and its metabolites with biogenic amine transporters. Bioorg. Med. Chem. 2000, 8, 2689-2692.